Rhumbline Advisers Sells 2,275 Shares of Fresenius Medical Care AG (NYSE:FMS)

Rhumbline Advisers lowered its position in shares of Fresenius Medical Care AG (NYSE:FMS) by 12.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,052 shares of the company’s stock after selling 2,275 shares during the period. Rhumbline Advisers’ holdings in Fresenius Medical Care were worth $363,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Wilmington Savings Fund Society FSB purchased a new position in shares of Fresenius Medical Care during the 3rd quarter valued at about $38,000. Venturi Wealth Management LLC raised its stake in shares of Fresenius Medical Care by 1,045.8% during the third quarter. Venturi Wealth Management LLC now owns 5,259 shares of the company’s stock worth $112,000 after acquiring an additional 4,800 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Fresenius Medical Care by 43.3% in the 4th quarter. GAMMA Investing LLC now owns 7,164 shares of the company’s stock worth $162,000 after acquiring an additional 2,166 shares during the last quarter. Franklin Street Advisors Inc. NC purchased a new stake in shares of Fresenius Medical Care in the 4th quarter valued at $201,000. Finally, Autumn Glory Partners LLC bought a new position in shares of Fresenius Medical Care during the 4th quarter valued at $208,000. 8.37% of the stock is currently owned by hedge funds and other institutional investors.

Fresenius Medical Care Trading Up 1.8 %

NYSE:FMS opened at $23.98 on Monday. The firm has a market capitalization of $14.07 billion, a P/E ratio of 19.82, a P/E/G ratio of 0.76 and a beta of 0.99. Fresenius Medical Care AG has a 52 week low of $17.93 and a 52 week high of $25.25. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42. The company has a fifty day moving average of $23.53 and a 200 day moving average of $22.05.

Analyst Ratings Changes

Several analysts have weighed in on FMS shares. Truist Financial boosted their price target on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the stock a “hold” rating in a research note on Monday, January 6th. Bank of America raised Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd. Finally, StockNews.com upgraded Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.